Leerink downgrades Synageva BioPharma, cites lack of visibility

Leerink downgrades Synageva BioPharma (GEVA) to Market Perform from Outperform.

Analyst Joseph Schwartz cites "lack of news flow and visibility into the market opportunity for sebelipase alfa."

Schwartz also says the stock may remain "relatively rangebound until ARISE pivotal trial data" due in H2 2014 or H1 2015.

Price target cut to $62 from $66.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs